Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02427's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.485 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Guanze Medical Information Industry (Holding) Co (HKSE:02427) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Guanze Medical Information Industry (Holding) Co 5-Year Yield-on-Cost % Related Terms
HKSE:02427 vs TMO, DHR, NTRA: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Guanze Medical Information Industry (Holding) Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guanze Medical Information Industry (Holding) Co 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
Guanze Medical Information Industry (Holding) Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Guanze Medical Information Industry (Holding) Co (HKSE:02427) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Guanze Medical Information Industry (Holding) Co and its competitors. Over the past decade, Guanze Medical Information Industry (Holding) Co's 5-Year Yield-on-Cost % has ranged from 2.10 to 6.56. According to the industry distribution chart, Guanze Medical Information Industry (Holding) Co ranks #999999 out of 60 companies in the Medical Diagnostics & Research industry.
Is Guanze Medical Information Industry (Holding) Co's 5-Year Yield-on-Cost % too high?
Guanze Medical Information Industry (Holding) Co's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 2.10 to a high of 6.56. Based on the distribution chart, Guanze Medical Information Industry (Holding) Co ranks #999999 out of 60 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Guanze Medical Information Industry (Holding) Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guanze Medical Information Industry (Holding) Co's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Guanze Medical Information Industry (Holding) Co ranks #999999 out of 60 companies for 5-Year Yield-on-Cost %. This places Guanze Medical Information Industry (Holding) Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.49. Historically, Guanze Medical Information Industry (Holding) Co's own 5-Year Yield-on-Cost % has ranged from 2.10 to 6.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.49, based on 60 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Guanze Medical Information Industry (Holding) Co and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guanze Medical Information Industry (Holding) Co's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guanze Medical Information Industry (Holding) Co stock overvalued right now?
Based on GuruFocus' analysis, Guanze Medical Information Industry (Holding) Co (HKSE:02427) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$2.22 — trading 722.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Guanze Medical Information Industry (Holding) Co's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Guanze Medical Information Industry (Holding) Co (HKSE:02427), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guanze Medical Information Industry (Holding) Co (HKSE:02427) Overvalued in 2026?
Based on GuruFocus' analysis, Guanze Medical Information Industry (Holding) Co stock appears to be overvalued.
The current stock price of HK$2.22 is trading 722.2% above its estimated GF Value™ of HK$0.27.
GuruFocus considers Guanze Medical Information Industry (Holding) Co to be Significantly Overvalued.
Key valuation signals for HKSE:02427:
5-Year Yield-on-Cost %: 0.00
GF Value™: HK$0.27 vs. price of HK$2.22 (722.2% above fair value)
No single metric tells the full story. See the HKSE:02427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guanze Medical Information Industry (Holding) Co Ltd is a medical imaging solutions provider, principally engaged in providing medical imaging film products and medical imaging cloud services in Shandong Province. The company generates the majority of its revenue from the PRC.
52GF Score
Get the complete analysis for HKSE:02427
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02427 has been successfully added to your 
